Editorial: New hope in battle against cancer
Successful clinical trials of a cancer vaccine — using mRNA technology — by Russian researchers have created hope among the scientific community
A new beacon of hope has now emerged in humanity’s war against cancer. An announcement from Russia about successful clinical trials of a cancer vaccine — using mRNA technology — has created excitement and hope among the scientific community. While it may be premature to celebrate the development as a breakthrough, it certainly marks a significant milestone in the global efforts to tame the deadly disease. mRNA (messenger RNA) technology involves “teaching” the immune system to recognise and destroy cancer cells by instructing cells to produce tumour-specific antigens. The technology is similar to the one used by Pfizer and Moderna in the development of Covid-19 vaccines. These personalised vaccines can be tailored to an individual’s tumour, potentially activating cellular immunity to target cancer cells effectively. Russian scientists have developed a personalised mRNA-based cancer vaccine called Enteromix. It has shown 100 per cent efficacy and safety in early-stage clinical trials involving 48 patients with colorectal cancer. And, there were no severe side effects reported. If this can be replicated in larger samples across countries, then the jab could mark a turning point in the global fight against the disease. Enteromix shots have shown significant results in shrinking tumours and slowing their growth, and have reportedly been found safe for repeated use. The vaccines will be first deployed against colorectal cancer, one of the most common malignancies. Vaccines against aggressive skin and brain cancers are reportedly in the pipeline. The vaccine has been developed by the National Medical Research Radiology Centre and the Engelhardt Institute of Molecular Biology in Russia.
However, Enteromix is not a one-size-fits-all jab. It uses RNA extracted from the patient’s own tumour cells to teach their immune system how to attack the cancer. Unlike traditional treatments for cancer, including chemotherapy or radiation, which attack healthy cells along with cancerous ones, the Russian vaccine is designed to be targeted and minimally invasive. The global oncology community is keenly watching further developments. If these results are validated through larger, rigorous trials, Enteromix could herald a new era: personalised, effective, and side-effect-free cancer treatment. For Indian patients, many of whom face high cancer burdens and variable access to care, such an advancement could be profoundly impactful. Cancer remains a major global health challenge, with the World Health Organization reporting that it accounted for nearly 10 million deaths in 2022, and there were nearly 20 million new cases of cancer reported during that year worldwide. This highlights the urgent need for innovative treatments to combat this ever-increasing burden. The International Agency for Research on Cancer projects that the number of cancer cases globally will rise to 35 million by 2050. The economic impact is staggering, with the cost of cancer care projected to exceed USD 25 trillion over the next 30 years.
